Ever since the first release of the tremendously popular, injectable wrinkle remover, BOTOX^®, the offerings of facial smoothers have continued to grow. In addition to BOTOX^®, cosmetic surgeons now have:

• Myobloc
• Dysport
• Xeomin^®

Now, the co-discoverer of BOTOX^®, Jean Carruthers, M.D. a clinical professor in the department of ophthalmology at the University of British Columbia in Vancouver, Canada, has released the results of a study on the latest neuromodulator which is being billed as lasting longer and being more effective than the previous versions of BOTOX^®.

(How the discovery of BOTOX^® came from pillow talk between Dr. Jean Carruthers and her dermatologist husband, Dr. Alastair Carruthers.)

The current study involved 268 patients at nine Canadian clinics; the test group all had moderate-to-severe glabella lines, the deep skin wrinkles between the eyebrows, just above the nose.

For the sake of easier identification, cosmetic surgeons are now identifying the various wrinkle removers as:

• daxbotulinumtoxinA – the latest version
• onabotulinumtoxinA – BOTOX^®
• abobotulinumtoxinA –Dysport
• IncobotulinumtoxinA –Xeomin^®

The testing was actually between daxbotulinumtoxinA, BOTOX^® and placebo. The study subjects were 76 to 92 percent women, with an average age of 47 to 50 years.

Physicians running the study and some patients measured their glabellar line severity about every four weeks for at least 24 weeks. The testing ran from December, 2014 to December, 2015.

Results?  100 percent of patients being tested with daxbotulinumtoxinA showed at least a one-point improvement in their glabella lines.

The BOTOX^® test group showed a 95 percent improvement while the placebo group scored a three percent improvement.

The testing additionally revealed the daxbotulinumtoxinA group recorded wrinkle removing lasting as long as 23.6 weeks while the BOTOX^® group showed results for 18.8 weeks. The placebo group had a 0 percent response.

All subjects receiving daxbotulinumtoxinA injections said they tolerated the injection doses well except for one subject who developed a possible migraine.

One more similar study will be conducted later.

Concluded the researchers at the study’s end: “Injectable daxbotulinumtoxinA could represent the first of a new generation of botulinum toxin treatments by offering an enhanced duration of response without compromising safety or tolerability.

“…daxbotulinumtoxinA deserves very careful study as it is currently the only new neuromodulator to challenge both the quality and response duration of BOTOX^®.”